Burlington, Massachusetts–(Newsfile Corp. – January 9, 2025) – Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced the appointment of Matthew W. McClure, M.D., as Chief Medical Officer (CMO). Dr. McClure’s distinguished track record in designing and directing successful early-to-late-stage clinical trials, which include several marketed products, further demonstrates Lifordi’s commitment to developing novel ADC-based therapeutics to address the high unmet needs of patients with autoimmune diseases.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
Click image above to view full announcement.
About LFD-200 and Lifordi’s Targeted ADC Delivery
Lifordi’s ADC-based delivery platform targets a cell surface protein (VISTA) mainly expressed on immune cells, including myeloid and lymphoid cells. The unique biologic properties of VISTA, including its rapid internalization and intracellular accumulation, make it ideal for an ADC approach. Preclinical studies of Lifordi’s lead ADC candidate, LFD-200, demonstrated a short serum half-life and long immune cell residency, as well as an ability to exert immunosuppressive function within these cells for an extended time without the toxicity associated with systemic delivery. Lifordi’s ADC-based platform is also being applied to target both innate and adaptive immune cells with different payloads such as nucleic acids. This innovative approach could offer a new way to target autoimmune and inflammatory conditions across various medical disciplines, including rheumatology, gastroenterology, pulmonology, and dermatology.
About Lifordi
Lifordi Immunotherapeutics, Inc. is leading the way in leveraging the success of antibody-drug conjugates (ADCs) to develop treatments for autoimmune and inflammatory disorders. The Company’s lead ADC, LFD-200, has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein (VISTA). As experienced drug developers in immunology and inflammatory diseases, together with expert clinical advisors, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture to support initial clinical data, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit www.lifordi.com.
Contacts:
Theresa McNeely
(508) 523-9511
tmcneely@lifordi.com
Source: Lifordi
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236568
View more news from Reportable, Inc.
You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.
If you no longer want to receive messages from us, you can click here to unsubscribe.
Anti-Spam Policy | Privacy Policy
The post Lifordi Immunotherapeutics Appoints Matthew W. McClure, M.D., as Chief Medical Officer first appeared on PressReleaseCC.
Lifordi Immunotherapeutics Appoints Matthew W. McClure, M.D., as Chief Medical Officer first appeared on Web and IT News.
Dr. Jared L. Roscoe, DC, IMD, discusses ozone therapy with an adult patient during a…
A healthcare specialist at Healing Frontiers administers non-invasive cold laser therapy in Wolfeboro, NH, to…
Berlin – Nov. 20, 2026 – LEVEL8 has announced a 20% Black Friday discount on…
table, td, td p, span, font {font-family: Arial, Helvetica, sans-serif ; font-size:11pt ;} View this…
Birmingham law firm Cory Watson Attorneys has 17 lawyers named to the 2026 Mid-South Super…
Built for mid-market and enterprise: Zoho Spend offers industry-first capabilities that combine travel, expense, procurement,…
This website uses cookies.